Ixabiso elisebenzayo lepu COVID-19 antigen kit yovavanyo olukhawulezayo lwe-AMRPA77

Iinkcukacha eziKhawulezayo

Ayina-invasive
Kulula ukuyisebenzisa
Kulula, akukho zixhobo zifunekayo
Ngokukhawuleza, fumana isiphumo kwimizuzu eyi-15

Ukupakishwa kunye nokuhanjiswa

Iinkcukacha

Ixabiso elisebenzayo lepu COVID-19 antigen kit yovavanyo olukhawulezayo lwe-AMRPA77

Umzekelo
1 uvavanyo / ikiti;Iimvavanyo ezi-5/ikhithi;Iimvavanyo ezili-10/ikhithi;Iimvavanyo ezingama-25/ikhithi;Iimvavanyo ezingama-50/ikhithi

Ixabiso elisebenzayo lepu COVID-19 antigen kit yovavanyo olukhawulezayo AMRPA77 AMRPA77 Usetyenziso olucetyiweyo
Imveliso yenzelwe ukufunyaniswa okusemgangathweni kwe-antigen ngokuchasene ne-SARS-CoV-2 kwiisampulu zeklinikhi (i-nasal swab).

Ixabiso elisebenzayo lepu COVID-19 antigen kit yovavanyo olukhawulezayo lwe-AMRPA77

Ayina-invasive
Kulula ukuyisebenzisa
Kulula, akukho zixhobo zifunekayo
Ngokukhawuleza, fumana isiphumo kwimizuzu eyi-15
Izinzile, ngokuchaneka okuphezulu
Ukungabizi, iindleko-ukuphumelela

Ixabiso elisebenzayo lepu COVID-19 antigen kit yovavanyo olukhawulezayo lwe-AMRPA77 Isishwankathelo
ICoronavirus, njengosapho olukhulu lwentsholongwane, yintsholongwane enye ene-RNA enemvulophu.Le ntsholongwane yaziwa ngokubangela izigulo ezikhulu ezifana nengqele, Middle East Respiratory Syndrome (MERS), kunye neSevere Acute Respiratory Syndrome (SARS).

Iprotein engundoqo ye-SARS-CoV-2 yiprotheyini ye-N (Nucleocapsid), eyinxalenye yeprotheyini ebekwe ngaphakathi kwintsholongwane.Ilondolozwe ngokwentelekiso phakathi kwe-β-coronavirus kwaye ihlala isetyenziswa njengesixhobo soxilongo lwe-coronavirus.I-ACE2, njengesamkeli esiphambili se-SARS-CoV-2 yokungena kwiiseli, ibaluleke kakhulu kuphando lwendlela yosulelo lwentsholongwane.

Ixabiso elisebenzayo lepu COVID-19 antigen kit yovavanyo olukhawulezayo lwe-AMRPA77 Umgaqo
Ikhadi lovavanyo lwangoku lisekelwe kwi-antibody-antigen reaction ethile kunye neteknoloji ye-immunoanalysis.Ikhadi lovavanyo liqulethe i-colloidal yegolide ebhalwe SARS-CoV-2 N protein monoclonal antibody eqatywe ngaphambili kwipadi yokudibanisa, ehambelana ne-SARS-CoV-2 N protein monoclonal antibody engashukumiyo kwindawo yovavanyo (T) kunye ne-antibody ehambelana nayo kumgangatho. indawo yolawulo (C).

Ngexesha lovavanyo, iprotein ye-N kwisampulu idibanisa negolide ye-colloidal ebhalwe SARS-CoV-2 N yeprotheyini ye-monoclonal antibody eqatywe ngaphambili kwipadi yokudibanisa.I-conjugates ifudukela phezulu phantsi kwe-capillary effect, kwaye emva koko ibanjwe yi-N protein ye-monoclonal antibody immobilized kwindawo yoVavanyo (T).

Okuphezulu imixholo ye-N protein kwisampulu, ngakumbi i-conjugates ibamba kwaye umbala omnyama kwindawo yovavanyo.

Ukuba akukho ntsholongwane kwisampuli okanye umxholo wentsholongwane ungaphantsi komda wokufumanisa, ngoko akukho mbala ubonakaliswe kwindawo yovavanyo (T).

Kungakhathaliseki ukuba ubukho okanye ukungabikho kwentsholongwane kwisampuli, umgca omfusa uya kubonakala kwindawo yokulawula umgangatho (C).

Umgca omfusa kwindawo yokulawula umgangatho (C) yinqobo yokugweba ukuba ngaba kukho isampuli eyaneleyo okanye hayi inkqubo yechromatography eqhelekileyo.